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Breast cancer is a morphologically and clinically heterogeneous disease; however, it is less clear how risk factors relate to tumour
features. We evaluated risk factors by tumour characteristics (histopathologic type, grade, size, and nodal status) in a population-
based case–control of 2386 breast cancers and 2502 controls in Poland. Use of a novel extension of the polytomous logistic
regression permitted simultaneous modelling of multiple tumour characteristics. Late age at first full-term birth was associated with
increased risk of large (42cm) tumours (odds ratios (95% confidence intervals) 1.19 (1.07–1.33) for a 5-year increase in age), but
not smaller tumours (P for heterogeneity adjusting for other tumour features (Phet)¼0.007). On the other hand, multiparity was
associated with reduced risk for small tumours (0.76 (0.68–0.86) per additional birth; Phet¼0.004). Consideration of all tumour
characteristics simultaneously revealed that current or recent use of combined hormone replacement therapy was associated with
risk of small (2.29 (1.66–3.15)) and grade 1 (3.36 (2.22–5.08)) tumours (Phet¼0.05 for size and 0.0008 for grade 1 vs 3), rather than
specific histopathologic types (Phet¼0.63 for ductal vs lobular). Finally, elevated body mass index was associated with larger tumour
size among both pre- and postmenopausal women (Phet¼0.05 and 0.0001, respectively). None of these relationships were
explained by hormone receptor status of the tumours. In conclusion, these data support distinctive risk factor relationships by tumour
characteristics of prognostic relevance. These findings might be useful in developing targeted prevention efforts.
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Breast cancers vary greatly in clinical behaviour, histopathologic
appearance, and molecular alterations. In addition, age-specific
incidence rates for breast cancer vary by histologic tumour type
(Anderson et al, 2004a), stage, and grade (Anderson et al, 2005)
and hormone receptor status (Yasui and Potter, 1999; Anderson
et al, 2002), suggesting that breast cancers might be aetiologically
distinct. Thus, demonstrating that specific epidemiologic risk
factors differ by clinically important tumour characteristics may
facilitate the development of targeted prevention efforts. However,
most epidemiologic studies performed to date have treated breast
cancer as a single disease with a common set of risk predictors.
Mounting albeit still limited evidence from epidemiological
studies suggests that breast cancer predictors vary by histological
type and hormone receptor status. Specifically, combined oestro-
gen and progestin hormone replacement therapy (HRT) (Li et al,
2000; Chen et al, 2002; Daling et al, 2002; Newcomb et al, 2002; Li
et al, 2003; Newcomer et al, 2003), and possibly late age at first
birth (LiVolsi et al, 1982; Ewertz and Duffy, 1988; Stalsberg et al,
1989) may be more strongly associated with lobular as compared
to ductal carcinomas. Epidemiologic data also suggest that
hormone-related risk factors vary by hormone receptor status
(Althuis et al, 2004).
In this report, we evaluated heterogeneity of established breast
cancer risk factors stratified by histopathological type, tumour
grade, size and nodal status, in a large population-based case–
control study in Poland. We used a novel statistical method to
disentangle the independent effects of these correlated tumour
features, as well as to adjust for hormone receptor status
(Chatterjee, 2004).
MATERIALS AND METHODS
Study population
A population-based breast cancer case–control study was
conducted in Poland between 2000 and 2003. Eligible cases were
women residing in Warsaw or Ło ´dz ´, 20–74 years of age, and
recently diagnosed with either histologically or cytologically
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recruited through a rapid identification system organized at five
participating hospitals, which identified about 90% of eligible
cases, and cancer registries. Eligible control subjects were residents
of Warsaw and Ło ´dz ´ without a history of breast cancer at
enrollment. The Polish Electronic System, a database with
demographic information from all residents of Poland, was used
to randomly select controls frequency matched to cases on city and
age in 5-year categories.
A total of 2386 cases (79% of eligibles) and 2502 controls (69%
of eligibles) agreed to participate in a personal interview regarding
known and suspected risk factors for breast cancer. The main
reasons of nonparticipation for cases and controls, respectively,
were refusal (19 and 25%) and unable to locate (2 and 6%).
Interviews were conducted a median of 6.8 weeks following
diagnosis for cases, and 2.4 weeks following identification for
controls. A signed informed consent to participate in the study was
obtained from all participants in accordance with the National
Cancer Institute and local Institutional Review Boards.
Risk factor information
Women were considered premenopausal if they reported having
natural menstrual periods at the time of interview, postmenopau-
sal if periods had stopped, and unclear menopausal status if HRT
use had been started before the natural periods stopped. Women
who reported having breastfed for 1 month or less were considered
as having never breastfed. Women who had used oral contra-
ceptives or oral HRT for 1 month or less were classified as non-
users. Users of oral HRT were further classified as current or
recent users (o2 years since last use) of combined (estrogen and
progesterone) HRT, past users (X2 years) of combined HRT, and
users of oestrogen or progesterone HRT alone. Body mass index
(BMI) was calculated using current weight (kg) divided by
standing height (m) squared as measured by a trained nurse. For
114 cases and 156 controls without measures of weight or height,
BMI was calculated using self-reported information. Women were
classified as non-drinkers if they reported having consumed 12 or
fewer alcoholic drinks in their lifetime or they reported consuming
less than one drink per month for 6 months without ever having
had more than five drinks on any one occasion. Women were
considered as having a history of benign breast disease if they
reported having had a benign breast biopsy 1 year prior to either
the diagnosis date (for cases) or the date of interview (for
controls).
Pathology information
Information about diagnostic and treatment procedures was
obtained from the medical records, and surgical pathology forms
that were completed after clinical sign-out of cases. The surgical
pathology form documented macroscopic (type and size of
surgical specimens and location and size of masses) and
microscopic (histopathologic diagnosis, grade, and status of
axillary and other lymph nodes) features. Results for oestrogen
receptor (ER) and progesterone receptor (PR) assays performed in
Poland were obtained from medical records. In 91% of cases with
receptor status information, assays were performed using im-
munohistochemistry, with biochemical methods used in the
remainder.
A single US pathologist (MES) reviewed haematoxylin and
eosin-stained slides to confirm case status and provide uniform
histologic classification. Final diagnoses for 1958 (82%) cases with
tumour slides available were based on the pathology review by
MES. Tumours were classified as ductal not otherwise specified
(NOS) or lobular if they demonstrated a predominant histopatho-
logic appearance; tumours containing mixed patterns were
designated as mixed carcinomas. Carcinomas were classified as
tubular or cribriform if the characteristic well-differentiated
patterns together accounted for 90% of the tumour area. Tubular
carcinomas and ductal carcinomas, NOS, grade 1 share morpho-
logic and clinical features. Accordingly, we combined these types
in some analyses. Studies have also suggested that low-grade ductal
or tubular carcinomas are related to infiltrative lobular carcino-
mas, with the former being the most highly differentiated and the
later the most undifferentiated extreme, a view that is supported
by the observation of patterns of low-grade ductal and lobular
carcinomas together in tubulo-lobular carcinomas (Fisher et al,
1977; Eusebi et al, 1979; Green et al, 1997). Thus, all of these types
have also been combined in some analyses. Grading was
performed according to Elston criteria (Elston and Ellis, 1998),
with the modification that mitotic rate was estimated.
For the remaining 428 cases without slides available for review,
the diagnosis in Poland was considered the final diagnosis. The
percent agreement between MES and Poland for invasive diagnosis
was 80% for ductal NOS, 68% for lobular, and 18% for mixed
carcinomas. The disagreement was mainly explained by reclassi-
fication of mixed type tumours as ductals or lobulars.
Statistical analysis
Logistic regression was used to estimate adjusted odds ratios
(ORs) and associated 95% confidence intervals (CI) from models
that included all risk factors simultaneously. Models included
continuous terms for age at menarche, number of full-term births,
age at first full-term birth, age at menopause and BMI, and dummy
variables for education levels, nulliparity, oral HRT use (never
user, current or recent use of combined HRT, past use of combined
HRT, use of other HRT), family history, history of a benign biopsy,
ever had a screening mammography and menopausal status
(premenopausal, postmenopausal, and unclear), current age in 5-
year categories and study site. Because the association between
BMI and breast cancer risk is known to differ by menopausal
status, our models included separate terms for pre-and post-
menopausal women. Estimation of ORs for different categories of
variables considered as continuous indicated that the log-linear
assumption was reasonable. Standard polytomous logistic regres-
sion was used to estimate ORs and 95% CI for different tumour
types. Heterogeneity between risk factor ORs for different tumour
types was assessed using logistic regression analyses restricted to
cases (case-only analyses). An extension of the polytomous logistic
regression model was used to evaluate heterogeneity in risk factor
ORs by multiple tumour characteristics simultaneously (Chatterjee,
2004). This method allowed us to evaluate which of several
correlated tumour features, that is, histopathologic type, grade,
size and nodal status, was most important in determining risk
factor associations. Oestrogen receptor and PR status were also
included as potential confounders. These analyses included cases
diagnosed with major histological subtypes (ductal carcinomas,
NOS; tubular carcinomas (classified as grade 1 ductal carcinoma,
NOS); lobular; and mixed carcinomas; total N¼1964). Odds ratios
(95% CI) and corresponding P-values (Phet) reported from these
analyses measure the association between tumour characteristics
and risk factors, similar to case-only analyses.
RESULTS
Characteristics of study population
About two-thirds of women were recruited in Warsaw and one-
third in Ło ´dz ´, with a mean age (7s.d.) of 56 (710) years.
Distribution of characteristics for cases and controls were
consistent with most established risk factors (Table 1). Use of
oral contraceptives or HRT, alcohol consumption, and mammo-
graphic screening were relatively uncommon in this population.
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an invasive component, with ductal carcinomas, NOS, accounting
for 58% of invasive cases, lobular carcinoma for 16%, and mixed
carcinoma for 12% (Table 2). Lobular and mixed carcinomas were
better differentiated than ductal carcinomas, NOS, whereas the
distributions of tumour size and axillary lymph node metastases
were similar across these tumour types (Table 3). Among ductal
carcinomas, NOS, 59% were ER positive and 50% were PR positive;
percentages for receptor detection were higher among lobular,
mixed, tubular, and tubulo-lobular carcinomas. Analyses for
heterogeneity between risk factors in the remainder of the
manuscript was restricted to tumours with known invasive
component (N¼2144).
Predictors of invasive breast cancer risk by tumour
histology
Overall, breast cancer risk was directly associated with higher level
of education, late age at first full-term birth, late age at menopause,
current or recent use of combined HRT, family history of breast
cancer and prior benign breast biopsy (Supplementary Table 4
online). On the other hand, breast cancer risk was inversely
associated with late age at menarche, multiparity, and high BMI in
pre-menopausal women (Supplementary Table 4 online). Among
postmenopausal women, BMI was not associated with overall
breast cancer risk. Oral contraceptive use and alcohol consump-
tion were uncommon and unrelated to overall risk (data not
shown); these factors were therefore not further considered.
Most predictors of risk were similar across histologic types,
with the exception of current or recent use of combined HRT,
which was associated with a greater risk for lobular and tubular as
compared to ductal carcinomas, NOS (Figure 1; Supplementary
Table 4 online). Current or recent use of combined HRT was also
associated with an increased risk of tubulo-lobular carcinoma
(N¼50; ORs (95% CI) of 1.85 (0.67–5.09)), although the precision
of the estimate was limited by small numbers. Risk factor
associations were similar for mixed and ductal carcinomas, NOS
(Figure 1; Supplementary Table 4 online).
Invasive breast cancer risk by tumour grade, size, and
nodal status
Differences in risk factors by tumour grade, size, and nodal status
were evaluated for the major histological types (ductal NOS,
tubular, lobular, and mixed tumours). For these analyses, tubular
tumours were included with ductal carcinomas, NOS, grade 1 since
they are a grade 1 ductal variant with similar morphological and
clinical features.
Delayed age at first full-term birth was associated with increased
risk for tumours that were large (42cm) (OR (95% CI)¼1.19
(1.07–1.33)) or with positive nodes (1.12 (1.08–1.35)). In contrast,
the reduced breast cancer risk associated with multiparity was
strongest for carcinomas that were small (p2cm) (0.76 (0.68–
0.86)) or node negative (0.82 (0.73–0.91)) (Figure 2; Supplemen-
tary Table 6 online). Increased breast cancer risk associated with
current or recent use of combined HRT was limited to low-grade
carcinomas (3.36 (2.22–5.08)) and tumours of small size (2.29
(1.66–315)) (Figure 2; Supplementary Tables 5 and 6 online). For
the combined group including grade 1 ductal NOS/tubular,
lobular, and tubulo-lobular carcinomas (N¼628), HRT use was
associated with an OR (95% CI) of 2.77 (1.96–3.91).
Elevated BMI in pre-menopausal women was associated with
reduced risks for tumours that were small or node negative.
Elevated BMI in postmenopausal women was not associated with
overall breast cancer risk; however, data suggested an association
with decreased risk of small or node negative tumours, and a small
increased risk of larger or node positive tumours (Figure 2;
Supplementary Table 6 online). Additional risk factor data are
shown as supplementary data (Supplementary Tables 5 and 6
online).
Table 1 Characteristics of the study population in the Polish Breast
Cancer Study
Cases Controls
Study characteristic N¼2386 N¼2502
Age in years (mean7s.d.) 55.8710.0 55.9710.1
Study site (% Warsaw) 65 63
Education level (% college degree) 25 15
Marital status (% married) 62 63
Age at menarche in years (mean7s.d.) 13.571.7 13.771.7
Parity (% parous) 86 89
Number of full-term births (mean7s.d.) 1.770.8 1.970.8
Age at first full-term birth (mean7s.d.) 24.574.6 23.674.2
Breastfeeding among women with live births
(% ever)
78 81
Oral contraceptive use (% ever) 12 10
Menopausal status (% postmenopausal) 75 70
Type of menopause among postmenopausal
women (% natural)
77 84
Age at menopause (mean7s.d.) 49.674.6 49.275.0
Use of oral HRT among postmenopausal
women (% ever)
Never 77 83
Current use of combined therapy
(o6 months)
74
Recent use of combined therapy
(6 months–o2 years)
42
Past use of combined therapy
(last use 2 or more years ago)
45
Ever used E or P alone 7 7
Duration of combined HRT among current/recent
users (mean7s.d.)
11.1712.5 9.7710.7
Current BMI among premenopausal (mean7s.d.) 25.474.9 26.475.1
Current BMI among postmenopausal (mean7s.d.) 27.975.4 28.675.4
Alcohol consumption (% ever) 33 32
Family history of breast cancer in first-degree
relatives (%)
10 6
Prior benign breast bipospy (%) 10 6
Ever had a screening mammogram (%) 62 54
BMI¼body mass index; HRT¼hormone replacement therapy.
Table 2 Histological types of breast cancer tumours in the Polish Breast
Cancer Study (N¼2386)
N %
Invasiveness
In situ 135 6
Invasive component 2144 94
Other 11 0.5
Unknown 96
a
Tumours with invasive component
b
Ductal NOS
c 1251 58
Lobular 341 16
Mixed 252 12
Tubular 119 6
Tubulobular 50 2
Medullary 16 1
Papillary 7 0.3
Mucinous 20 1
Other primary carcinoma 83 4
Other malignant tumour 3 0.1
aCases with cytological but no histological confirmation.
bTwo cases had missing
information.
cNOS¼not otherwise specified.
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In this section, we evaluate the association between predictors of
breast cancer risk and different tumour characteristics simulta-
neously using a novel extension of polytomous logistic regression
to account for multiple disease outcomes (Chatterjee, 2004). Odds
ratios (95% CI) from these analyses and their corresponding
P-values (Phet; shown in Supplementary Tables 5 and 6 online)
measure the association between tumour characteristics and risk
factors, similar to case-only analyses.
Late age at first full-term birth and multiparity were associated
with larger tumour size: OR (95% CI) for size 42cm vs
p2cm¼1.23 (1.06–1.44), Phet¼0.007 for 5-year increase in age
at first birth; and 1.30 (1.09–1.55), Phet¼0.004 for each additional
full-term birth. However, associations between these risk factors
and nodal status found in the standard polytomous logistic
regression models were no longer significant in models consider-
ing multiple tumour characteristics simultaneously (Supplemen-
tary Tables 5 and 6 online).
Recent or current use of combined HRT was significantly related
to low tumour grade (0.38 (0.23–0.65), Phet¼0.0003, and 0.29
(0.14–0.60), Phet¼0.0008 for grades 2 and 3 compared to grade 1,
respectively), and smaller tumour size (0.60 (0.36–0.99),
Phet¼0.05 for tumours 42cm vs p2cm), but the association
with lobular type suggested in the standard logisitic analyses
(Figure 1) was no longer significant (1.14 (0.66–2.00), Phet¼0.63
for lobular vs ductal tumours). This model indicated that HRT use
is related to tumour grade, independent of the histological type.
Indeed, stratification of lobular tumours by grade 1 (N¼60) and
grades 2 or 3 (N¼250) indicated a stronger increase in breast
cancer risk for grade 1 (3.62 (1.52–8.63)) vs grades 2 or 3 (2.18
(1.30–3.65)), Phet¼0.12.
Elevated BMI in pre- and postmenopausal women was
associated with larger tumour size (1.28 (1.00–1.64), Phet¼0.05;
1.30 (1.14–1.49), Phet¼0.0001, respectively); however, the associa-
tion with nodal status was present for pre-menopausal women
(1.28 (1.00–1.62) Phet¼0.04) but not for postmenopausal women
(1.04 (0.92–1.19), Phet¼0.51).
DISCUSSION
Analysis of data from this large population-based case–control
study provides convincing evidence that breast cancer risk factors
differ by clinically important tumour features, including histo-
pathological type, grade, size, and nodal status. Thus, exposures
that influence the risk of developing breast cancer might also affect
the biology and clinical behaviour of the tumours that arise. These
findings parallel data suggesting that molecular profiles of breast
cancers are generally fixed at inception and represent important
determinants of clinical behavior (Lacroix et al, 2004). Accord-
ingly, understanding relationships between risk factors for breast
cancer and tumour characteristics could have implications for
screening and prevention.
Similar to a previous case–control study (Wohlfahrt et al, 1999),
we found that delayed age at first full-term birth was associated
with increased risk of tumours that were large or node positive,
whereas multiparity was associated with reduced risk for small
tumours. Furthermore, analyses using a novel statistical method,
which considered all tumour characteristics simultaneously,
indicated that late age at first full-term birth and multiparity were
more strongly related to larger tumour size than nodal invasion.
Thus, these reproductive factors might act primarily to enhance
tumour growth rate or delay detection. Either explanation would
Table 3 Characteristics of different histological types of invasive breast cancer tumours in the Polish Breast Cancer Study
Ductal NOS
a Lobular Mixed Tubular Tubulo-lobular
N¼1251 N¼342 N¼252 N¼119 N¼50
N % N % N % N % N %
Grade
1 (well differentiated) 121 11 60 19 40 17 112 100 33 66
2 (moderately differentiated) 591 51 228 74 160 66 0 17 34
3 (poorly differentiated) 437 38 22 7 41 17 0 0 0
Unknown 102 32 11 7 0
Size (cm)
T1: p2.0
T1a: p0.5 13 1 2 1 1 0 11 9 1 2
T1b: 40.5–p1.0 116 10 34 11 27 11 37 31 7 14
T1c: 41.0–p2.0 466 41 127 41 101 43 53 45 34 68
T2: 42–p5 479 43 133 42 99 42 7 6 8 16
T3: 455 2 5 1 7 5 9 4 1 1 9 0 0
Unknown 125 29 15 0
Number of positive nodes
None 677 59 193 62 121 51 93 89 34 68
1-3 285 25 65 21 71 30 9 9 9 18
X 4 177 16 55 18 43 18 3 3 7 14
Unknown 112 29 17 14
ER status
Negative 398 41 56 20 59 30 10 12 4 10
Positive 576 59 224 80 139 70 76 88 35 90
Unknown 277 62 54 33 11
PR status
Negative 483 50 107 38 66 33 27 32 7 18
Positive 487 50 173 62 132 67 58 68 32 82
Unknown 281 62 54 34 11
Age at diagnosis (mean7s.d.) 55.2 710.4 57.0 79.3 56.8 710.0 55.7 78.1 53.8 78.6
aNOS¼not otherwise specified.
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women. Although the mechanisms responsible for the associations
of delayed age at first birth with poor prognostic features are
unknown, continuous exposure to cyclic hormones uninterrupted
by the dramatic differentiation and remodelling effects of
pregnancy on breast tissue might play an important role. In
contrast to some previous reports (LiVolsi et al, 1982; Ewertz and
Duffy, 1988; Stalsberg et al, 1989), we and others (Morrison, 1976;
Wohlfahrt et al, 1999) did not find that late age at first full-term
birth was more strongly associated with lobular as compared with
ductal carcinoma, NOS.
As previously reported, we found that HRT use was more
strongly related to lobular (Gapstur et al, 1999; Li et al, 2000; Chen
et al, 2002; Daling et al, 2002; Newcomb et al, 2002; Li et al, 2003;
Newcomer et al, 2003) and tubular (Manjer et al, 2001) carcinomas
than to other histopathologic types. In addition, we observed a
stronger association between HRT use and risk for grade 1 ductal
carcinomas, NOS, and tubulo-lobular carcinomas. This observa-
tion is consistent with the hypothesis that low-grade ductal or
tubular and lobular carcinomas are aetiologically related and may
represent the morphologic extremes of tumours (with the former
being the most highly differentiated and the later the most
undifferentiated extremes) that share a common carcinogenic
pathway (Fisher et al, 1977; Eusebi et al, 1979; Green et al, 1997).
This report and others have found that combined HRT use is
also associated with low grade or small tumours (Collaborative
Group on Hormonal Factors in Breast Cancer, 1997; Gapstur et al,
1999; Li et al, 2000; Manjer et al, 2001). Consideration of all
tumour characteristics simultaneously in our analyses indicated
that HRT use is primarily associated with tumour grade and to a
lesser extent, with tumour size, whereas associations with
histopathologic type or nodal status were not significant. It is
possible that these findings reflect a detection bias associated with
increased screening among HRT users; however, we found similar
associations among screened and unscreened women (data not
shown). In addition, it is known that HRT increases breast density,
which decreases the sensitivity of mammography, and that
mammography is insensitive in detecting lobular carcinomas.
From a public health perspective, it is reassuring that the excess
breast cancer risk associated with HRT use is related mainly to
tumours with good prognostic features.
Findings from this case–control study provide support for an
association between obesity and later stage at diagnosis, as it has
been reported in most previous studies, mostly case-series
(Daniell, 1988; Ingram et al, 1989; Verreault et al, 1989; Reeves
et al, 1996; Jones et al, 1997; Hall et al, 1999; Cui et al, 2002), with a
few exceptions (Donegan et al, 1978; Howson et al, 1986). In
addition, consideration of all tumour characteristics simulta-
neously, suggested that obesity is primarily associated with larger
tumour size rather than nodal status, particularly among
postmenopausal women. Case–control analyses indicated that
the association between obesity and larger tumour size in pre-
menopausal women reflects a protection of obesity against small
but not larger tumours, as it has been previously reported (Hall
et al, 1999). This finding could reflect failed detection of smaller
tumours by self or medical examination since tumours are more
difficult to palpate in obese women. Among postmenopausal
women only, high BMI was also associated with a small increase in
risk for large tumours, which is consistent with growth enhance-
ment due to higher levels of circulating hormones among obese
than non-obese postmenopausal women. Previous studies have
suggested that BMI is associated with hormone receptor-positive
tumours which could confound the observed association with
tumour size (Althuis et al, 2004). However, in our data,
associations between BMI and tumour size were independent of
hormone receptor status.
It has been suggested that tumours with poor prognostic
features (i.e. high grade, large size, node positive, ER negative)
differ aetiologically (Mueller, 1988; Anderson et al, 2004b; Li et al,
2005). Our data support this notion, challenging the view that
tumour aggressiveness results entirely from stochastic molecular
events that occur over time (Hellman and Harris, 2000). It is
unclear whether risk factors directly affect prognosis, indirectly
affect outcomes by influencing tumour characteristics at presenta-
tion or are unrelated to the clinical course.
Strengths of our study include large sample size, high
participation rates, and standardised histopathologic assessment
by an independent pathology review. In addition, we considered
different tumour characteristics simultaneously using a novel
statistical method (Chatterjee, 2004) which allowed us to evaluate
the independent association of these characteristics, and adjust for
hormone receptor status of the tumour. Although this study
population had higher percentage of tumours with adverse
prognostic features than those observed in other Western
populations, most known breast cancer risk factors were present
in similar magnitude as previously reported, indicating that our
findings should be generalisable to other populations.
In summary, this population-based study provides evidence that
breast cancer risk factors are associated with clinically important
tumour characteristics, suggesting that aetiological factors may
affect the biological behaviour of breast cancers. In addition, these
data suggest that postmenopausal women who are nulliparous
have later ages at first birth and are obese might benefit from more
frequent screening.
ORs by histology Risk factors
BMI (Post-menopausal)
BMI (Pre-menopausal)
Current/recent HRT use (1)
Age at menopause
No. of full-term births
Age at 1st full-term birth
0.1 0.2 0.4 0.6 0.81.0 2.0 4.0 6.08.010.0
Odds ratio
Age at menarche
Figure 1 Predictors of invasive breast cancer risk in the Polish Breast
Cancer Study by histological subtypes. Odds ratios (95% CI) for ductal
carcinomas, NOS (N¼1,251) are shown in black, for lobular carcinomas
(N¼342) in blue, for tubular carcinomas (N¼119) in red, and for mixed
carcinoma (N¼252) in green. Numbers in brackets denote statistically
significant heterogeneity of ORs for lobular, tubular, and mixed compared
to ductal carcinomas, NOS, respectively, based on standard polytomous
logistic regression among cases: (1) 0.13, 0.002, and 0.98. Analyses are
adjusted for age, study site, menopausal status, education level, family
history, prior benign breast biopsy, screening mammogram, and all other
factors shown in the figure. Comparison groups are 5-year increases for
ages at menarche, first full-term birth, and menopause; each additional birth
for number of full-term births; never HRT users for current or recent use of
combined HRT; 5 unit increases for BMI.
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